Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
The collaboration covers BCL-2 selective inhibitor candidates - developed by Servier and Vernalis - currently entering clinical development. Proteins of the BCL-2 family are crucial regulators of apoptosis (programmed cell death).
“These new compounds further extends Servier’s portfolio beyond kinase inhibitors, HDAC inhibitors and immunitherapeutic products,” said Dr Jean-Pierre Abastado of Servier’s Center of Therapeutic Innovation in Oncology.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.